Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended March 31, 2026
Business Overview: NAII operates in two primary segments: private-label contract manufacturing for nutritional supplements and patent/trademark licensing for beta-alanine ingredients (CarnoSyn®). The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2026 | 9 Months Ended Mar 31, 2026 | 9 Months Ended Mar 31, 2025 |
|---|---|---|---|
| Net Sales | $35,482 | $108,007 | $95,994 |
| Gross Profit | $383 | $7,271 | $5,754 |
| Gross Margin % | 1.1% | 6.7% | 6.0% |
| Net Loss | $(4,311) | $(7,155) | $(6,359) |
| Loss Per Share (Diluted) | $(0.72) | $(1.19) | $(1.07) |
| Cash and Equivalents (Mar 31, 2026) | $9,196 | - | - |
| Operating Cash Flow (9 Months) | $(7,850) | $(7,850) | $2,587 |
| Total Debt (Line of Credit + Term Note) | $18,700 | - | - |
Note: Debt figures reflect outstanding balances as of March 31, 2026 ($10.0M line of credit + $8.7M term note).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 23% quarter-over-quarter and 13% year-over-year (9-month). Private-label contract manufacturing sales drove this growth, up 25% (Q/Q) and 14% (Y/Y), attributed to increased orders from a major customer and new customer acquisitions.
- Margin Compression: Gross profit margin collapsed to 1.1% in the most recent quarter (down from 6.3% prior year) due to unfavorable product mix and factory underutilization. However, the 9-month margin improved to 6.7% (from 6.0%) due to volume increases.
- Licensing Decline: Patent and trademark licensing revenue decreased 11% over the nine-month period, primarily due to lower instant-release CarnoSyn® raw material sales, partially offset by new TriBsyn® product sales.
- Cash Flow Deterioration: Operating cash flow swung from a positive $2.6M in the prior year to a negative $7.9M usage, driven by a $5.9M increase in accounts receivable and a $5.1M increase in inventory.
- Debt Covenant Breach: The company was not in compliance with maximum net loss and fixed charge coverage ratio covenants under its Wells Fargo credit agreement for the three and nine months ended March 31, 2026.
Guidance, Outlook, and Risks
- Outlook: Management anticipates increased sales revenue in Q4 fiscal 2026 compared to Q3 2026 and Q4 2025. However, the company expects to report a net loss for Q4 and the full fiscal year 2026.
- Strategic Initiatives:
- Product Launches: Launched CarnoSyn® 4X (April 2026) and expanded applications for TriBsyn® (May 2026) to target sports nutrition, wellness, and medical nutrition channels.
- Asset Divestiture: The Board approved the sale of the corporate headquarters building to unlock capital, improve liquidity, and fund working capital needs.
- Debt Refinancing (Subsequent Event): On May 18, 2026, NAII entered a new Loan and Security Agreement with Legacy Corporate Lending, LLC. This facility includes an $11.0M term loan and a $20.0M working capital line, refinancing the Wells Fargo debt. The real estate loan initially bears interest at 14.0% (reverting to 5.0% + SOFR after appraisal).
- Risks and Contingencies:
- Customer Concentration: One customer accounted for 27% of net sales in the first nine months of 2026.
- Legal Proceedings: A tentative settlement of $1.25M plus legal fees was reached regarding a former employee class action lawsuit; court approval is pending.
- Geopolitical & Tariffs: Risks include supply chain disruptions from conflicts in the Middle East/Europe and potential adverse effects from new U.S. tariffs on raw materials like beta-alanine.
- IRS Dispute: The IRS denied a portion of the Employee Retention Tax Credit (ERTC) claim for Q3 2021; the company is contesting this denial.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the terms of the new Legacy Corporate Lending agreement and confirm the company is now in compliance with fixed charge coverage ratios.
- Headquarters Sale: Monitor the status of the corporate headquarters building sale to confirm proceeds and timing of liquidity injection.
- Customer Concentration: Assess the stability of the largest customer (27% of sales) and the impact of their order cycles on future revenue.
- Margin Recovery: Evaluate whether factory utilization improvements in Q4 will restore gross margins to historical levels or if the 1.1% Q3 margin indicates structural cost issues.
- Legal Settlement: Confirm the final court approval of the $1.25M employee lawsuit settlement and any additional legal fees incurred.
- Interest Rate Exposure: Review the impact of the initial 14.0% interest rate on the new real estate term loan until the appraisal is completed.